Vantas™ (histrelin implant) is a sterile non-biodegradable, diffusion-controlled reservoir drug delivery system designed to deliver histrelin continuously for 12 months upon subcutaneous implantation. The Vantas implant contains 50 mg of histrelin acetate. Histrelin acetate is a synthetic nonapeptide analogue of the naturally occurring gonadotropin releasing hormone (GnRH) or luteinizing hormone releasing hormone (LH-RH). The sterile Vantas implantation device (provided with the implant) is used to insert the implant subcutaneously in the inner aspect of the upper arm. After 12 months, the implant must be removed. At the time the implant is removed, another implant may be inserted to continue therapy.
Vantas is indicated in the palliative treatment of advanced prostate cancer .
Media Articles Related to Vantas (Histrelin Implant)
Test Spares Men Unnecessary Biopsies for Prostate Cancer
Source: Medscape Hematology-Oncology Headlines [2014.07.24]
The epigenetic Confirm MDX assay for prostate cancer, with its 90% negative predictive value, can reduce unnecessary biopsies 10-fold, according to results from 2 studies.
Medscape Medical News
Unnecessary repeat biopsies for prostate cancer may be eliminated by new accurate epigenetic test
Source: Genetics News From Medical News Today [2014.07.24]
More than one million prostate biopsies are performed each year in the U.S. alone, including many repeat biopsies for fear of cancer missed.
Prostate cancer controlled for 10 years by robot-assisted surgery
Source: Prostate / Prostate Cancer News From Medical News Today [2014.07.21]
Robot-assisted surgery to remove cancerous prostate glands is effective in controlling the disease for 10 years, according to a new study led by researchers at Henry Ford Hospital.
Can Bike Riding Up Prostate Cancer Risk?
Source: MedicineNet Prostate Cancer Specialty [2014.07.21]
Title: Can Bike Riding Up Prostate Cancer Risk?
Category: Health News
Created: 7/18/2014 12:35:00 PM
Last Editorial Review: 7/21/2014 12:00:00 AM
Early onset prostate cancer a newly identified, more aggressive subtype often linked to genetic mutations
Source: Prostate / Prostate Cancer News From Medical News Today [2014.07.18]
The number of younger men diagnosed with prostate cancer has increased nearly 6-fold in the last 20 years, and the disease is more likely to be aggressive in these younger men, according to a new...
Published Studies Related to Vantas (Histrelin Implant)
Long-term efficacy and tolerability of once-yearly histrelin acetate subcutaneous implant in patients with advanced prostate cancer. [2011.08.18]
Study Type - Therapy (individual cohort) Level of Evidence 2b What's known on the subject? and What does the study add? Androgen deprivation therapy with a gonadotropin-releasing hormone agonist is an effective option for the palliative treatment of advanced prostate cancer. This study demonstrated the safety and efficacy of the histrelin acetate implant over successive one year treatment cycles for up to four years in an open-label extension trial. OBJECTIVE: * To evaluate the efficacy and tolerability of a once-yearly histrelin implant during an open-label extension of a pivotal study... CONCLUSIONS: * The once-yearly histrelin implant maintained testosterone suppression for repeated treatment cycles and was generally well tolerated. * The histrelin implant provides a clinically attractive option for long-term androgen deprivation therapy in patients with advanced prostate cancer seeking fewer office visits and repeated injections. (c) 2011 THE AUTHORS. BJU INTERNATIONAL (c) 2011 BJU INTERNATIONAL.
Analysis of testosterone suppression in men receiving histrelin, a novel GnRH agonist for the treatment of prostate cancer. [2010.08]
CONCLUSION: The GnRH agonist histrelin successfully suppressed testosterone over the entire study period. This effect was measured across a number of different clinical definitions of PSA response and clinical risk. The GnRH agonist therefore offers an effective therapy option in hormone treatment of prostate cancer.
Free alpha-subunit is the most sensitive marker of gonadotropin recovery after treatment of central precocious puberty with the histrelin implant. [2010.06]
BACKGROUND: Gonadotropin free alpha-subunit (FAS) levels paradoxically increase during GnRH agonist (GnRHa) treatment of central precocious puberty (CPP). The histrelin implant suppresses gonadotropins and estradiol (E(2)) levels for 1 yr, but effects on FAS have not been described. OBJECTIVES: We aimed to determine whether FAS levels remain elevated during treatment with the implant, to assess the dynamics of FAS after removal, and to ascertain the reliability of FAS for monitoring gonadotropin secretion... CONCLUSIONS: Compared to LH, FSH, and E(2), FAS responds more rapidly to implant removal and represents the most sensitive indicator of gonadotropin recovery after histrelin implant treatment.
Histrelin: in advanced prostate cancer. [2010.03.26]
Histrelin is a gonadotropin-releasing hormone agonist available in a diffusion-controlled reservoir drug delivery system for subcutaneous implantation. The subcutaneous histrelin implant provided sustained suppression of serum testosterone, luteinizing hormone (LH) and prostate-specific antigen levels for up to 1 year in patients with advanced prostate cancer in two phase II or III trials...
Drug-induced liver injury caused by the histrelin (Vantus) subcutaneous implant. [2010.01]
Drug-induced liver injury (DILI) is the leading cause of acute hepatic failure in the United States... The case of a patient with liver injury following a subcutaneous histrelin (Vantus) implant as therapy for advanced prostate cancer is presented.
Clinical Trials Related to Vantas (Histrelin Implant)
Prospective Multicentre Non-interventional Study of VANTASï¿½ for the Treatment of Patients With Advanced Prostate Cancer [Recruiting]
The aim of this non-interventional (observational) study is to document, in collaboration
with established urologists in Scandinavia, experience gained from routine use of Vantas®
for the treatment of patients with advanced prostate cancer. In this observational study
particular attention will be directed to treatment duration, quality of life and patient and
physician acceptance of the medicinal product for long-term therapy. Patient-based
measurement parameters such as quality of life and degree of satisfaction will allow
registration of information that extends beyond the clinical parameters. The knowledge
gathered will enable patient acceptance of long-term therapy to be evaluated. Clinical
outcome will also be documented by measuring serum testosterone and prostate specific
antigen (PSA) levels.